Merck taps Promega for new Keytruda microsatellite instability diagnostic

Illustration of three DNA helices
Promega’s PCR-based testing methods have been used as a lab-developed test and in research use only since 2004. (Darwin Laganzon)

Merck & Co. will work with Promega to develop the biological analysis company’s microsatellite instability technology into an official, on-label companion diagnostic for its Keytruda immunotherapy in solid tumors.

The global collaboration will start with its eyes on regulatory approvals in the U.S. and China, plus the possibility of expanding its work into additional territories.

Promega’s diagnostic platform aims to measure the accumulation of insertion or deletion errors in genetic code, also known as indels, caused by the deficient proteins in the mismatch-repair system that fail to catch them, and are found in certain types of cancers.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Unlike other DNA-based, molecular screening options, Promega MSI technology uses five monomorphic mononucleotides, which is recommended by the National Cancer Institute,” said Jeff Bacher, a senior research scientist at Promega.

RELATED: Merck's quarterly Keytruda sales soar past $3B, but analysts fret over future growth

“Our test uses a sensitive and specific panel of markers for detection of MSI status and offers valuable insight to help inform physicians on how best to treat patients with cancer including those likely to benefit from immune checkpoint inhibitor treatment,” Bacher said. Keytruda was the first therapy approved by the FDA to treat solid tumors in any organ of the body, based instead on the cancer’s genetic code and MSI status.

Promega’s PCR-based testing methods have been used as a lab-developed test and in research use only for acquiring MSI status since 2004, though it was recently granted innovation status and priority review by China’s National Medical Products Administration.

“It is gratifying to see our MSI technology have such meaning within the oncology community,” said Bill Linton, president and CEO of the Madison, Wisconsin-based company. “Promega developed this technology well over a decade ago and our long-term commitment to R&D helped evolve its use.”

In addition to the Merck collaboration, Promega said it plans pursue regulatory clearances for a separate MSI in vitro diagnostic in the U.S., China and Europe, with the goal of commercial launches in the first half of next year.

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.